{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:16Z","timestamp":1793371516776,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>An 8-year-11-month-old girl with severe atopic dermatitis had previously received treatments including topical hydrocortisone butyrate, pimecrolimus, tacrolimus, hormone ointment encapsulation, and narrowband ultraviolet B (NB-UVB) phototherapy. She also took oral antihistamines such as cetirizine and loratadine, but these interventions provided limited relief, and her pruritus persisted. In August 2023, she began dupilumab therapy with a 400\u2005mg subcutaneous loading dose, followed by 200\u2005mg subcutaneous injections every two weeks. Vitiligo developed three months after dupilumab initiation in this child with severe atopic dermatitis and improved with combination therapy while dupilumab was continued. Together with previously published reports, this observation supports a possible temporal association between dupilumab exposure and vitiligo development; however, causality cannot be established from the currently available evidence.<\/jats:p>","DOI":"10.3389\/fmed.2026.1947337","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:33Z","timestamp":1790574273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Vitiligo developing during dupilumab treatment in a child with atopic dermatitis: a case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Peng","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Dalian Women and Children\u2019s Medical Group","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglei","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dalian Women and Children\u2019s Medical Group","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/biomedicines10071639","article-title":"Current concepts of vitiligo immunopathogenesis","volume":"10","author":"Hla\u010da","year":"2022","journal-title":"Biomedicines"},{"key":"B2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.35541\/cjd.20210885","article-title":"Treatment of atopic dermatitis with dupilumab: an expert consensus","volume":"55","year":"2022","journal-title":"Chin J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1346-8138.16764","article-title":"Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study","volume":"50","author":"Napolitano","year":"2023","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"adv00580","DOI":"10.2340\/actadv.v101.545","article-title":"Rapid enlargement of vitiligo vulgaris after initiation of dupilumab for atopic dermatitis: a case report","volume":"101","author":"Takeoka","year":"2021","journal-title":"Acta Derm-Venereol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1111\/jdv.19132","article-title":"Vitiligo induced by dupilumab treatment: a case series","volume":"37","author":"Ren","year":"2023","journal-title":"J Eur Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.35541\/cjd.20220021","article-title":"Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis","volume":"55","author":"Huang","year":"2022","journal-title":"Chin J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/ddg.15564","article-title":"Two cases of dupilumab-induced vitiligo","volume":"22","author":"Ferreirinha","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jdcr.2023.03.025","article-title":"Vitiligo during dupilumab therapy","volume":"36","author":"Picone","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/JAA.S492614","article-title":"Concurrent refractory atopic dermatitis and generalized vitiligo successfully treated with abrocitinib: a case report","volume":"17","author":"Shao","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B10","first-page":"293","article-title":"A case report and literature review of vitiligo-like skin changes after treatment with dupilumab","volume":"18","author":"Bian","year":"2024","journal-title":"Chin J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/1346-8138.17698","article-title":"Vitiligo associated with type 2 immune inhibitors: fAERS analysis and literature review","volume":"52","author":"Lu","year":"2025","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0332079","DOI":"10.1371\/journal.pone.0332079","article-title":"Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database","volume":"20","author":"Shen","year":"2025","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jocd.13263","article-title":"Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis","volume":"19","author":"Acharya","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13223-021-00597-4","article-title":"Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis","volume":"17","author":"Lu","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1539997","DOI":"10.3389\/fimmu.2025.1539997","article-title":"Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.4110\/in.2024.24.e33","article-title":"Th pathways in immune-mediated skin disorders: a guide for strategic treatment decisions","volume":"24","author":"Speeckaert","year":"2024","journal-title":"Immune Netw"},{"key":"B17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jaci.2010.11.050","article-title":"Interleukins, from 1 to 37, and interferon-\u03b3: receptors, functions, and roles in diseases","volume":"127","author":"Akdis","year":"2011","journal-title":"J Allergy Clin Immun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.it.2005.04.001","article-title":"The \u2019supervirus\u2019? Lessons from IL-4-expressing poxviruses","volume":"26","author":"Stanford","year":"2005","journal-title":"Trends Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-a) invitiligo-new insight into pathogenesis of disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"872458","DOI":"10.3389\/fimmu.2022.872458","article-title":"Skin interstitial fluid and plasma multiplex cytokine analysis reveals IFN-\u03b3 signatures and granzyme B as useful biomarker for activity, severity and prognosis assessment in vitiligo","volume":"13","author":"Ng","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1947337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:34Z","timestamp":1790574274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1947337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":21,"alternative-id":["10.3389\/fmed.2026.1947337"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1947337","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1947337"}}